9 Meters Biopharma (Nasdaq:NMTR) - Hisse Senedi Fiyatı, Haberler ve Analizler

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NMTR Stoklara Genel Bakış

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Daha fazla detay

NMTR temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Gelirin yılda 56.58% oranında artması öngörülüyor

Risk Analizi

Anlamlı bir piyasa değeri yok ( $3M )

1 yıldan az nakit akışı var

Geliri 1 milyon ABD dolarından az ( $0 )

Negatif hissedar öz sermayesi

+ 3 daha fazla risk

9 Meters Biopharma, Inc. Rakipler

SenesTech

NasdaqCM:SNES

US$2.4m

Akanda

NasdaqCM:AKAN

US$1.9m

InMed Pharmaceuticals

NasdaqCM:INM

US$3.3m

China Pharma Holdings

NYSEAM:CPHI

US$3.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti 9 Meters Biopharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.20
52 Haftanın En Yüksek Seviyesi	US$6.56
52 Haftanın En Düşük Seviyesi	US$0.18
Beta	1.48
11 Aylık Değişim	-72.75%
3 Aylık Değişim	-85.45%
1 Yıllık Değişim	-96.00%
33 Yıllık Değişim	-98.32%
5 Yıllık Değişim	-99.85%
Halka arzdan bu yana değişim	-99.83%

Son Haberler & Güncellemeler

Recent updates

9 Meters Biopharma to execute 1-for-20 reverse stock split

Oct 17

9 Meters Biopharma GAAP EPS of -$0.04 in-line

Aug 15

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

Jun 14

9 Meters drug effective in treating rare COVID-19 complication in children

May 26

9 Meters Bio gains 5% on Adage Capital stake disclosure

Dec 29

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

Dec 21

9 Meters Bio launches equity offering

Dec 11

Hissedar Getirileri

	NMTR	US Pharmaceuticals	US Pazar
7D	-71.1%	1.6%	2.2%
1Y	-96.0%	9.9%	31.6%

Getiri vs. Endüstri: NMTR geçen yıl % 9.9 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: NMTR geçen yıl % 31.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is NMTR's price volatile compared to industry and market?
NMTR volatility
NMTR Average Weekly Movement	22.4%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: NMTR hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: NMTR 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 17% dan 22% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	10	Bethany Sensenig	www.9meters.com

9 Meters Biopharma, Inc. Temel Bilgiler Özeti

9 Meters Biopharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NMTR temel i̇stati̇sti̇kler
Piyasa değeri	US$2.82m
Kazançlar(TTM)	-US$46.28m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.1x

F/K Oranı

NMTR aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NMTR gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$46.28m
Kazançlar	-US$46.28m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.20
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	-80.5%

NMTR uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

This company listing is no longer active

NMTR Stoklara Genel Bakış

Ödüller

Risk Analizi

9 Meters Biopharma, Inc. Rakipler

NasdaqCM:SNES

US$2.4m

NasdaqCM:AKAN

US$1.9m

NasdaqCM:INM

US$3.3m

NYSEAM:CPHI

US$3.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

Price target decreased by 43% to US$10.25

Consensus EPS estimates fall by 43%

Price target decreased by 32% to US$22.68

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

Price target decreased by 43% to US$10.25

Consensus EPS estimates fall by 43%

Price target decreased by 32% to US$22.68

Price target increased by 18% to US$39.20

Price target decreased by 15% to US$33.12

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

Price target decreased to US$57.00

9 Meters Biopharma to execute 1-for-20 reverse stock split

Price target increased to US$3.40

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma GAAP EPS of -$0.04 in-line

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

Price target decreased to US$3.33

Independent Chairman recently bought US$50k worth of stock

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought US$56k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Price target decreased to US$4.33

President recently bought US$53k worth of stock

President recently bought US$53k worth of stock

Independent Chairman recently bought US$100k worth of stock

Director Sandeep Laumas has left the company

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters drug effective in treating rare COVID-19 complication in children

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: US$1.50

New 90-day high: US$1.37

9 Meters Bio gains 5% on Adage Capital stake disclosure

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

9 Meters Bio launches equity offering

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

New 90-day high: US$0.89

New 90-day high: US$0.85

Independent Chairman recently bought US$96k worth of stock

Independent Chairman recently bought US$56k worth of stock

New 90-day low - US$0.47

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index